Modalis Therapeutics Corporation Logo

Modalis Therapeutics Corporation

Develops epigenome editing therapies for genetic muscular, heart, and CNS disorders.

4883 | T

Overview

Corporate Details

ISIN(s):
JP3922600006
LEI:
Country:
Japan
Address:
中央区日本橋本町三丁目11番5号
Sector:
Mining and quarrying
Industry:
Mining of non-ferrous metal ores

Description

Modalis Therapeutics Corporation is a biotechnology company that pioneers the development of therapeutics for genetic diseases through epigenome editing. The company's proprietary core platform, CRISPR-GNDM®, is an advanced technology designed to regulate gene expression by selectively activating or suppressing specific genes without altering the underlying DNA sequence. This system utilizes a compact editor that can be delivered to target cells via AAV vectors. Modalis operates a hybrid business model, advancing therapeutic candidates through both in-house development pipelines for subsequent licensing and collaborative partnerships. Its development pipeline is focused on addressing unmet medical needs in muscular disorders, cardiomyopathy, and central nervous system (CNS) disorders.

Unlock This Filing & Millions More

You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.

Filings

You have of free filing views remaining. Upgrade for unlimited access.
Quick Filters:

Filters

Clear
Bulk Actions:
Date Filing Language Size Actions
2025-08-14 08:48
Registration Form
訂正有価証券届出書(組込方式)
Japanese 237.5 KB
2025-08-14 08:31
Regulatory News Service
確認書
Japanese 8.9 KB
2025-08-14 08:30
Interim Report
半期報告書-第10期(2025/01/01-2025/12/31)
Japanese 266.6 KB
2025-08-07 08:32
Registration Form
有価証券届出書(組込方式)
Japanese 334.6 KB
2025-03-28 07:52
Post-Annual General Meeting Information
臨時報告書
Japanese 28.4 KB
2025-03-27 08:32
Governance Information
内部統制報告書-第9期(2024/01/01-2024/12/31)
Japanese 24.1 KB
2025-03-27 08:30
Registration Form
確認書
Japanese 8.7 KB
2025-03-27 08:29
Annual Report
有価証券報告書-第9期(2024/01/01-2024/12/31)
Japanese 2.1 MB
2025-02-21 07:31
Audit Report / Information
臨時報告書
Japanese 21.5 KB
2024-08-13 08:14
Registration Form
訂正有価証券届出書(組込方式)
Japanese 293.9 KB
2024-08-13 07:58
Interim Report
半期報告書-第9期(2024/01/01-2024/12/31)
Japanese 249.6 KB
2024-08-13 07:58
Registration Form
確認書
Japanese 8.9 KB
2024-08-07 08:01
Registration Form
有価証券届出書(組込方式)
Japanese 495.2 KB
2024-05-14 06:00
Quarterly Report
四半期報告書-第9期第1四半期(2024/01/01-2024/03/31)
Japanese 166.1 KB
2024-05-14 06:00
Report Publication Announcement
確認書
Japanese 8.9 KB

Automate Your Workflow. Get a real-time feed of all Modalis Therapeutics Corporation filings delivered via API.

Explore Data Feeds →

Market Data

Market Data Not Available

Financials & KPIs

No data available

Unlock Full Financials for Modalis Therapeutics Corporation

This data is available as part of our premium data solutions. Contact our team for access.

Need More History? Access decades of standardized financials for Modalis Therapeutics Corporation via our API.

Get Historical Data →

Insider Transactions

Date Insider Name Position Type Shares Value
No insider transactions recorded for this company.

Peer Companies

MATCHING SERVICE JAPAN CO.,LTD. Logo
Specialized recruitment firm connecting legal, finance, and accounting experts with top companies.
Japan
6539
Material Group inc. Logo
A professional services firm offering PR consulting, marketing, and brand strategy.
Japan
156A
Medesis Pharma S.A. Logo
Develops therapies for CNS disorders and radiation exposure via a drug delivery platform.
France
ALMDP
Medicofarma Biotech Spolka Akcyjna Logo
A biotech R&D company developing innovative drugs and devices with a focus on oncology therapies.
Poland
MDB
Medpace Holdings, Inc. Logo
Global CRO providing full-service clinical development to biotech, pharma & medical device industries.
United States of America
MEDP
Develops biomarker-based precision therapies for oncology and other incurable diseases.
South Korea
235980
Medrx Co.,Ltd. Logo
Develops and licenses transdermal drug delivery systems for the pharmaceutical industry.
Japan
4586
Developing nanomedicines and drug delivery systems for oncology, hematology, and diagnostics.
Malaysia
N/A
A holding company driving regional growth by supporting construction, HR, and nursing care businesses.
Japan
7369
Mendus Logo
Developing immunotherapies using dendritic cells to prevent cancer recurrence and improve survival.
Sweden
IMMU

Talk to a Data Expert

Have a question? We'll get back to you promptly.